Dyax (NASDAQ:DYAX) Growing Patient Base Right Strategy Says Needham

Dyax Corp. (NASDAQ:DYAX) has a fan of their strategy of building out their patient base which will eventually lead to increased sales of KALBITOR.

Needham said, "Looking into 2011, we expect to see gradual conversion of the metric of growth from patient enrollment numbers, which remains the key driver of the stock in the near-term, to KALBITOR revenue generation. We believe the Company has embarked on the right strategy by focusing on building a steadily growing patient base that we believe will directly translate to KABITOR sales over time."

Needham & Company maintains a "Buy" rating on Dyax Corp., which closed Wednesday at $2.09, down $0.01, or 0.48 percent. Needham has a price target of $8 on them.